ifosfamide has been researched along with Blood Poisoning in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 9.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 9.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with malignant pleural mesothelioma." | 5.10 | Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. ( Bakhshandeh, A; Bruns, I; Dalhoff, K; Demedts, A; Eberhardt, K; Ehlers, EM; Gatzemeier, U; Gruber, Y; Hegewisch-Becker, S; Kaukel, E; Kohlmann, T; Koschel, G; Peters, SO; Robins, HI; Traynor, A; Wiedemann, GJ; Zumschlinge, R, 2003) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 5.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Totadri, S | 1 |
| Bansal, D | 1 |
| Rao, KLN | 1 |
| Jain, R | 1 |
| Saxena, AK | 1 |
| Kapoor, R | 1 |
| Samujh, R | 1 |
| Trehan, A | 1 |
| Bakhshandeh, A | 1 |
| Bruns, I | 1 |
| Traynor, A | 1 |
| Robins, HI | 1 |
| Eberhardt, K | 1 |
| Demedts, A | 1 |
| Kaukel, E | 1 |
| Koschel, G | 1 |
| Gatzemeier, U | 1 |
| Kohlmann, T | 1 |
| Dalhoff, K | 1 |
| Ehlers, EM | 1 |
| Gruber, Y | 1 |
| Zumschlinge, R | 1 |
| Hegewisch-Becker, S | 1 |
| Peters, SO | 1 |
| Wiedemann, GJ | 1 |
| Davidson, KL | 1 |
| Devaney, MB | 1 |
| Tighe, JE | 1 |
| Rogers, SY | 1 |
| Dunlop, DJ | 1 |
| Mackie, MJ | 1 |
| Thomas, RV | 1 |
| Johnson, PR | 1 |
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Müller, S | 1 |
| Metz, K | 1 |
| Moritz, T | 1 |
| Seeber, S | 1 |
| Nowrousian, MR | 1 |
| Lowis, SP | 1 |
| Pearson, AD | 1 |
| Reid, MM | 1 |
| Craft, AW | 1 |
| Chen, YM | 1 |
| Wu, MF | 1 |
| Perng, RP | 1 |
| Chou, CM | 1 |
| Yang, KY | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Liu, JM | 1 |
| Whang-Peng, J | 1 |
| Theis, JG | 2 |
| Chan, HS | 2 |
| Greenberg, ML | 2 |
| Malkin, D | 2 |
| Karaskov, V | 2 |
| Moncica, I | 2 |
| Koren, G | 2 |
| Doyle, J | 2 |
| Krämer, A | 1 |
| Andrassy, K | 1 |
| Ho, AD | 1 |
| Breitfeld, PP | 1 |
| Lyden, E | 1 |
| Raney, RB | 1 |
| Teot, LA | 1 |
| Wharam, M | 1 |
| Lobe, T | 1 |
| Crist, WM | 1 |
| Maurer, HM | 1 |
| Donaldson, SS | 1 |
| Ruymann, FB | 1 |
| Ghosn, M | 1 |
| Droz, JP | 1 |
| Theodore, C | 1 |
| Pico, JL | 1 |
| Baume, D | 1 |
| Spielmann, M | 1 |
| Ostronoff, M | 1 |
| Moran, A | 1 |
| Salloum, E | 1 |
| Kramar, A | 1 |
7 trials available for ifosfamide and Blood Poisoning
| Article | Year |
|---|---|
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dexame | 2003 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child, Preschool; C | 1993 |
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Drug Admin | 1997 |
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
4 other studies available for ifosfamide and Blood Poisoning
| Article | Year |
|---|---|
Challenges in the management of localized Ewing sarcoma in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2020 |
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 2000 |
Renal failure after bone marrow transplantation.
Topics: Acute Kidney Injury; Bone Marrow Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Kidn | 2001 |
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etopo | 1988 |